Tempus AI Gets FDA Green Light for Simpler Tumor-Only Cancer Test
Tempus AI gets FDA approval for tumor-only cancer DNA test, making diagnosis easier and boosting future revenue potential.
/ 11 items
#TEM↓
Tempus AI Q1 2026: Revenue Beats Expectations, But Stock Drops on Wider Losses
Tempus AI revenue rose 36% to $348M, but losses widened. Stock fell ~7% after weaker profit and cautious outlook.
TD Securities Sees Strong 2026 Growth for Tempus AI
TD Cowen upgraded Tempus AI to Buy, $65 target, citing strong growth in AI pharma tools despite recent stock drop.
Tempus AI Gets a $100 Price Target – Why Mizuho Sees Big Upside in Precision Oncology
Mizuho starts coverage on Tempus AI with Outperform rating and $100 price target. Leader in AI-powered precision oncology in a $40B market growing 30% annually—growth undervalued today.
Nancy Pelosi's Latest Stock Moves: Big Bets on Tech Giants
Nancy Pelosi disclosed major stock transactions in January 2026, including exercising options on Amazon, Google, and Nvidia while selling Apple shares worth millions.
Tempus AI Hits Major Milestone with $1.1 Billion in Contracts
Tempus AI achieves record $1.1 billion in total contract value, partners with 70+ pharmaceutical companies, and reports 31% revenue growth in 2025.